Search results
Results from the WOW.Com Content Network
Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.
The acquisition included Karuna's lead asset, KarXT, an investigational muscarinic antipsychotic combination of Xanomeline and Trospium. [86] In November 2023, the FDA accepted Karuna Therapeutics' NDA for KarXT, for the treatment of schizophrenia in adults. [87] The acquisition of Karuna Therapeutics was completed in March 2024. [88]
Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna's stock on Thursday.
By Michael Erman and Manas Mishra (Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power ...
[19] [20] As of 2020, he was on the board of directors or is a trustee of several organizations, including serving as chairman of the Board of the Foundation for the NIH (FNIH) [21] and as a Director of Alnylam Pharmaceuticals, [22] Sage Therapeutics, [23] Voyager Therapeutics [24] and Karuna Pharmaceuticals. [25]
Skip to main content
Previous logo. Companies which PureTech Health founded include Karuna Pharmaceuticals, [4] Gelesis, which has received FDA approval as a treatment for weight management, [5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders, [6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases, [7] and Follica which is ...
If Karuna is successful, its drug would offer relief to a large patient population. According to the World Health Organization, schizophrenia affects approximately 24 million people, or one in 300 ...